GlassScriptPhysician profile
Capri Dishman
NPI 1992428304
$915.74
in general payments reported to CMS, 2019-2025
11 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $184 · 2024: $374 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.84 |
| Education | $190.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $479.07 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $80.60 | 2023-2025 | |
| Organon LLC | $66.95 | 2023-2025 | Nexplanon |
| Abbvie INC. | $53.35 | 2023 | |
| Biogen, INC. | $53.00 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $48.24 | 2025 | |
| Exeltis, USA INC. | $37.53 | 2023-2025 | Slynd |
| Alexion Pharmaceuticals, INC. | $31.04 | 2023 | Ultomiris |
| Molnlycke Health Care US, LLC | $28.94 | 2024 | Mepilex Border Post-Op Ag, Avance |
| Hologic Sales and Service, LLC | $18.94 | 2025 | Novasure |
| Sumitomo Pharma America, INC. | $18.08 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Capri Dishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.